Pfizer’s Litfulo (ritlecitinib) Receives EC’s Approval for Adolescents and Adults with Severe Alopecia Areata
- The EC has granted marketing authorization to Litfulo for adults & adolescents aged ≥12yrs. with sev. alopecia areata. The approval was based on the (ALLEGRO) trial program incl. P-IIb/III trial (ALLEGRO) of Litfulo vs PBO in 718 patients
- The results showed that 13.4% of adults and adolescents achieved ≥90% scalp hair coverage (SALT ≤10) after 24wks. with Litfulo (50mg) vs 1.5% with PBO, PGI-C response was measured, 49.2% vs 9.2% reported a response of “moderate” to “great” improvement in alopecia areata at 24wks.
- The marketing authorization is valid in all 27 EU member states, Iceland, Liechtenstein & Norway. Litfulo is the first and only treatment to selectively inhibit JAK3 & tyrosine kinase expressed in the hepatocellular carcinoma family of kinases
Ref: Businesswire | Image: Pfizer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.